Quotient Sciences and CPI have signed a memorandum of understanding to form a joint venture focused on accelerating RNA-based drug development. The collaboration will integrate both companies’ technologies to streamline the creation of mRNA therapeutics.

The venture will combine Quotient’s Translational Pharmaceutics platform with CPI’s expertise in RNA synthesis and lipid nanoparticle (LNP) encapsulation. Together, they aim to deliver a first-of-its-kind solution for mRNA drug product development.

Thierry Van Nieuwenhove, CEO at Quotient Sciences, said: “This is a pivotal moment for RNA drug development. The combined innovation and deep technical expertise of Quotient and CPI will enable developers to benefit from a vastly accelerated supply chain, with clinical batches going from plasmid to clinical dose in as little as two months.”

The joint venture will offer integrated mRNA synthesis, LNP formulation, clinical manufacturing and early-phase testing. This approach allows developers to adjust dose and formulation based on real-time clinical data, potentially improving outcomes in delivery-sensitive modalities.

Frank Millar, CEO at CPI, said: “We’re proud to be partnering with Quotient Sciences on this initiative, which represents a bold step forward for the RNA ecosystem. Our shared vision is to enable scalable and sustainable development pathways for mRNA therapies that meet global health challenges head-on.”

Translational Pharmaceutics has supported over 500 programmes globally for small molecule and peptide candidates. This new venture marks its expansion into mRNA therapeutics.

Further details including the venture’s name, branding and operational roadmap will be announced as the collaboration progresses.

eXmoor Pharma and Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS) have announced a strategic partnership to provide integrated support for developers of autologous and allogeneic cell therapies. The collaboration combines donor material expertise with GMP manufacturing capabilities.

The partnership offers a complete service spanning donor sourcing, screening, apheresis collection, process development and clinical-grade manufacturing. It aims to simplify the path from starting material to clinical supply while prioritising patient and donor welfare.

Anthony Nolan’s CT&LS will supply starting material through its donor register of over 900,000 HLA-typed individuals, bioinformatics tools, cord blood programme and a new apheresis centre in Nottingham. The organisation brings over 50 years of donor care experience.

eXmoor will process the material at its GMP facility in Bristol, offering fill-finish, process development and manufacturing services. The company has passed Anthony Nolan CT&LS’s ethical review board, ensuring aligned standards across the collaboration.

Lucy Foley, CEO of eXmoor Pharma, said: “We are proud to partner with Anthony Nolan’s CT&LS, powered by a UK institution with unmatched expertise in donor services and ethical sourcing. Together, we can offer cell therapy developers a truly integrated path from donor to patient.”

David Bennett, Director of Business Development for Anthony Nolan’s Cell Therapy and Lab Services, said: “Our 50+ years of experience in working with donors and our large and diverse register, make Anthony Nolan’s CT&LS the obvious choice for partners like eXmoor who are looking to accelerate therapy development.”

The partnership is designed to reduce complexity, shorten timelines and uphold the highest ethical and clinical standards in cell therapy development.